Connexall and VigiLanz Combine Antimicrobial Stewardship with Intelligent Routing to Improve Patient Safety
BOULDER, CO & TORONTO, ON (PRWEB) February 28, 2018 -- Connexall and VigiLanz Combine Antimicrobial Stewardship with Intelligent Routing to Improve Patient Safety
Connexall and VigiLanz, both named Category Leaders in the 2018 Best in KLAS awards, have teamed up to deliver time-sensitive information related to antimicrobial stewardship (AMS) to increase patient safety and improve outcomes at hospitals.
The VigiLanz AMS platform aggregates information from physician order entries, laboratory and pathology reports, and the EHR to provide continuous surveillance of patients. Connexall integrates with VigiLanz and the EHR to intelligently route data quickly and reliably to the assigned care team for the affected patient. This guides the care team to ensure safe and appropriate use of antibiotics.
“AMS has emerged as a central component of highly effective care quality and safety strategies, and success requires the ability to rapidly transform data into action,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “This partnership between VigiLanz and Connexall does just that, providing our customers with a robust AMS solution that leverages the power of two KLAS category leaders to drive improved patient outcomes.”
“Connexall is delighted to partner with VigiLanz to enhance antimicrobial stewardship programs for the benefit of patients.” stated David Tavares, GlobeStar/Connexall CEO. “Our intelligent routing capabilities ensure that the assigned care team is notified promptly and reliably to deliver the care the patients require.” continued Tavares.
To learn more about this progressive solution, please visit VigiLanz at Booth #2674 and Connexall at Booth #8105 at HIMSS18.
About Connexall
Connexall, ranked number one and named Category Leader in the 2015/2016, 2017, and 2018 Best in KLAS awards, is an enterprise-grade event management and control platform that delivers hospital-wide interoperability to people, systems, tasks, and devices. Its capabilities act as a backbone for clinical workflow, communicating the right information to the right person, at the right time, on the right device. Based on more than 20 years of R&D efforts, the Class II medical device software is completely vendor-neutral and device-independent. Connexall has offices in Canada, the United States, Brazil, Portugal and Hong Kong and works with well over a thousand of the world’s most renowned and progressive hospitals and health systems. For more information please visit http://www.connexall.com.
About VigiLanz
Founded in 2001, VigiLanz Corporation (http://www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.
Connexall Contact
Betsy Berken-Zaslav, US Marketing Manager
(866) 556-3377
bzaslav(at)connexall(dot)com
VigiLanz Contact
Erik Johnson, Vice President of Marketing
VigiLanz Corp.
ejohnson(at)vigilanzcorp(dot)com
952.232.6391
Betsy Berken-Zaslav, Connexall, https://connexall.com/, (866) 556-3377, [email protected]
Share this article